Nikki J
Moderator
- Joined
- Mar 22, 2012
- Messages
- 17,246
- Reason
- PALS
- Diagnosis
- 04/2014
- Country
- US
- State
- MA
- City
- Boston
Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
- PHOENIX Study Did Not Meet Prespecified Primary or Secondary Endpoints - Data From 664-Participant Study Reinforce That AMX0035 is Generally Safe and Well-Tolerated - Within the Next Eight Weeks, Amylyx Will Continue to Engage With Regulatory Authorities and the ALS Community to Share Topline...
www.amylyx.com
As you know it was approved after a phase 2 on that data and also ole. It wasn’t conditional but there was an exchange during the ADCOMM where it was asked what if it fails phase 3? Amylyx didn’t outright say they would withdraw it but hinted and apparently they are now “considering” withdrawing it. I imagine insurance will no longer pay